Offered by the Lentivirus Construct Core of the COBRE for Stem Cells & Aging
Multiple SARS-CoV-2 variants are circulating globally since the COVID-19 pandemic started in early 2020. Most notable strains include D614 (prevalent in early 2020), G614 (dominant since the spring of 2020), and N501Y (currently in the U.K. (B.1.1.7), South Africa (501Y.V2) and Ohio (COH.20G/501Y)) variants. Much of the research effort is focused on the mutations in the spike protein that locks onto a human protein ACE2 on the cells to cause infection.
At the Lentivirus Construct Core, we have developed a pseudotyped SARS-CoV-2 virus which has a lentiviral core but with the SARS-CoV-2 spike protein on its envelope (Zhou et al., Oncotarget, 2020, 11(46): 4201-4223).
The pseudoviruses infect human lung epithelial cells in an ACE2-dependent manner and confer the expression of luciferase and/or a fluorescence protein ZsGreen in infected cells for imaging and quantification. The pseudoviruses can only accomplish a single infection cycle and are replication incompetent, thus require only BSL-2 level containment.
- Pseudovirus with SARS-CoV-2 N501Y spike (a common mutation in the U.K., South Africa and Ohio strains in the winter of 2020/2021)
- Pseudovirus with SARS-CoV-2 G614 spike (dominant strain since the spring of 2020)
- Pseudovirus with SARS-CoV-2 D614 spike (prevalent strain in early 2020)
- Pseudovirus with SARS-CoV-2 R685A spike (furin-cleavage site mutated)
- Lentivirus for human ACE2 over-expression with puromycin selection
- Stable HeLa cell line over-expressing hACE2 (highly efficient in pseudovirus cell entry)
- Stem Cells and Aging COBRE Investigators: $450 per batch*
- Academic and Non-profit Investigators: $600 per batch*
- Other Investigators: $750 per batch*
* Total number of concentrated virus will be between 107 and 108 for each batch.
Olin Liang, Ph.D.
Director, Lentivirus Construct Core
COBRE Center for Stem Cells and Aging
CORO West Research Building
One Hoppin Street
Providence, RI 02903
Tel: 401-444-9039 (work) | 617-816-8885 (cell)
Email: [email protected]